[Ip-health] India-Japan trade pact to leave IP laws untouched
k0b0 at yahoo.com
Wed Sep 15 09:09:46 PDT 2010
India-Japan trade pact to leave IP laws untouched
Joe C Mathew / New Delhi September 14, 2010, 0:17 IST
The India-Japan Comprehensive Economic Partnership Agreement (Cepa), expected to
be signed towards the end of this year, will not call for any amendments to the
existing intellectual property (IP) laws in either of the partner countries.
Indian and Japanese officials, who approved in principle the Cepa draft, have
chosen the legalistic model over a quid pro quo (give and take) model for
concluding their IP-related negotiations, one of the biggest stumbling blocks
that delayed the conclusion of the three-year-long negotiations, it is learnt.
The decision should come as a major relief to the domestic pharmaceutical
industry and the patient groups that were lobbying hard against the attempts of
global multinational firms to introduce IP provisions beyond what has been
mandated under the TRIPS (Trade Related Aspects of Intellectual Property Rights)
provisions of the World Trade Organization through bilateral trade agreements.
With the Indo-Japan trade pact almost sealed, the focus of the lobbyists will
now be on Indo-EU negotiations, where similar demands are still in the
According to government sources, clauses that link the patent status of a
medicine to the drug approval process and exclusivity for use of clinical trial
data generated by innovator companies, will not have a mention in Cepa.
“The agreement will focus on the commitment to honour the existing IP laws in
respective countries. Beyond that, there will be no mention about any IP
enforcement procedures that may require amendments to existing laws”, the
Indian and Japanese officials had met on September 9 to fine-tune the draft
before a possible ratification of the agreement by both the countries during the
coming visit of Prime Minister Manmohan Singh to Japan. It should be noted that
the quid pro quo and legalistic models were the two negotiation options put up
by the Department of Industrial Policy and Promotion, the nodal department for
IP issues, during its discussions with various ministries early this year.
The majority of respondents, including the Department of Pharmaceuticals, had
preferred the legalistic model, which involves no changes in the existing legal
The approach has been the same towards other intellectual properties such as
geographical indications, trademarks, etc.
Cepa is expected to slash tariffs on more than 8,000 products including drugs,
apparel, agricultural products and machinery, thereby increasing the bilateral
trade between both countries to $20 billion by 2012-13 from $13 billion at
While Japan ranks 10th among India’s export destinations, India stands 26th
among its export destinations. India’s exports to Japan comprise mostly of raw
materials, minerals, marine products, iron ore, handicrafts, cotton, carpets and
leather garments. Its imports from that country include heavy machines,
transport equipment and pharmaceuticals.
More information about the Ip-health